Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914651 | 0.91 | HDAC8 (0.50) | HDAC8PTPN1NPSR1F10NAMPT | |
| SCHEMBL4649758 | 0.87 | POLB (0.46) | NPSR1POLBNAMPT | |
| SCHEMBL4803652 | 0.86 | PTPN1 (0.42) | HDAC8PTPN1NPSR1 | |
| SCHEMBL4808286 | 0.86 | KMT2A (0.50) | HDAC8PTPN1POLBNAMPT | |
| SCHEMBL4808295 | 0.86 | KMT2A (0.50) | HDAC8PTPN1POLBNAMPT | |
| SCHEMBL4922008 | 0.82 | HDAC8 (0.51) | HDAC8PTPN1NPSR1NAMPT | |
| SCHEMBL4822180 | 0.82 | PTPN1 (0.46) | HDAC8PTPN1POLBNAMPT | |
| SCHEMBL14067982 | 0.80 | PTPN1 (0.48) | HDAC8PTPN1POLB | |
| SCHEMBL12586629 | 0.80 | PTPN1 (0.48) | HDAC8PTPN1POLB | |
| SCHEMBL4649542 | 0.80 | NAMPT (0.41) | HDAC8POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | HDAC8 3671/4885PTPN1 1948/4885NPSR1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.